SG10201604747WA - Use of n-hydroxysuccinimide to improve conjugate stability - Google Patents
Use of n-hydroxysuccinimide to improve conjugate stabilityInfo
- Publication number
- SG10201604747WA SG10201604747WA SG10201604747WA SG10201604747WA SG10201604747WA SG 10201604747W A SG10201604747W A SG 10201604747WA SG 10201604747W A SG10201604747W A SG 10201604747WA SG 10201604747W A SG10201604747W A SG 10201604747WA SG 10201604747W A SG10201604747W A SG 10201604747WA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxysuccinimide
- conjugate stability
- improve conjugate
- improve
- stability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570139P | 2011-12-13 | 2011-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604747WA true SG10201604747WA (en) | 2016-08-30 |
Family
ID=48613179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604747WA SG10201604747WA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
| SG11201403179QA SG11201403179QA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403179QA SG11201403179QA (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140350228A1 (en) |
| EP (1) | EP2790724A4 (en) |
| JP (1) | JP2015504869A (en) |
| KR (1) | KR20140107418A (en) |
| CN (1) | CN104093425A (en) |
| AU (1) | AU2012352210A1 (en) |
| BR (1) | BR112014014464A2 (en) |
| CA (1) | CA2859444A1 (en) |
| EA (1) | EA201491173A1 (en) |
| HK (1) | HK1203364A1 (en) |
| IL (1) | IL233086A0 (en) |
| MX (1) | MX2014007125A (en) |
| SG (2) | SG10201604747WA (en) |
| WO (1) | WO2013090590A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52470B (en) | 2005-08-24 | 2013-02-28 | Immunogen Inc. | Process for preparing maytansinoid antibody conjugates |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| EA201991268A3 (en) | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | OBTAINING MAYTANSINOID-ANTIBODIES CONJUGATES IN ONE-STEP METHOD |
| NZ707091A (en) | 2012-10-04 | 2018-12-21 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| JP6744212B2 (en) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | Enzymatic binding of polypeptides |
| CN106267225B (en) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | Trimaleimide-type linker and use thereof |
| CN109152845B (en) | 2016-04-14 | 2022-07-12 | 宝力泰锐克斯有限公司 | Comprising at least two (-CH) s within a ring2-CH2Conjugates of linkers of-O-) units and conjugation reagents |
| GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| CN113336823A (en) * | 2021-05-28 | 2021-09-03 | 联宁（苏州）生物制药有限公司 | Synthetic method for antibody-conjugated drug linker LND1067 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2835829B1 (en) * | 2002-02-13 | 2007-09-14 | Centre Nat Rech Scient | NOVEL PROCESS FOR THE PREPARATION OF DNA OR PROTEIN BIOPUCES AND THEIR APPLICATIONS |
| DE10242076A1 (en) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever |
| RS52470B (en) * | 2005-08-24 | 2013-02-28 | Immunogen Inc. | Process for preparing maytansinoid antibody conjugates |
| CA2629815C (en) * | 2005-11-14 | 2014-08-12 | University Of Southern California | Integrin-binding small molecules |
| ES2435779T3 (en) * | 2007-07-19 | 2013-12-23 | Sanofi | Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use |
| EP3100745B1 (en) * | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
| SG10201810743WA (en) * | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
-
2012
- 2012-12-13 WO PCT/US2012/069527 patent/WO2013090590A1/en active Application Filing
- 2012-12-13 KR KR20147019143A patent/KR20140107418A/en not_active Application Discontinuation
- 2012-12-13 EA EA201491173A patent/EA201491173A1/en unknown
- 2012-12-13 CN CN201280068773.2A patent/CN104093425A/en active Pending
- 2012-12-13 JP JP2014547433A patent/JP2015504869A/en active Pending
- 2012-12-13 MX MX2014007125A patent/MX2014007125A/en unknown
- 2012-12-13 EP EP12856692.4A patent/EP2790724A4/en not_active Withdrawn
- 2012-12-13 BR BR112014014464A patent/BR112014014464A2/en not_active IP Right Cessation
- 2012-12-13 SG SG10201604747WA patent/SG10201604747WA/en unknown
- 2012-12-13 CA CA 2859444 patent/CA2859444A1/en not_active Abandoned
- 2012-12-13 AU AU2012352210A patent/AU2012352210A1/en not_active Abandoned
- 2012-12-13 SG SG11201403179QA patent/SG11201403179QA/en unknown
- 2012-12-13 US US14/365,305 patent/US20140350228A1/en not_active Abandoned
-
2014
- 2014-06-12 IL IL233086A patent/IL233086A0/en unknown
-
2015
- 2015-04-21 HK HK15103864.0A patent/HK1203364A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140350228A1 (en) | 2014-11-27 |
| CN104093425A (en) | 2014-10-08 |
| HK1203364A1 (en) | 2015-10-30 |
| CA2859444A1 (en) | 2013-06-20 |
| KR20140107418A (en) | 2014-09-04 |
| SG11201403179QA (en) | 2014-07-30 |
| AU2012352210A1 (en) | 2014-07-24 |
| EP2790724A4 (en) | 2015-08-05 |
| WO2013090590A1 (en) | 2013-06-20 |
| EA201491173A1 (en) | 2014-11-28 |
| MX2014007125A (en) | 2015-04-16 |
| JP2015504869A (en) | 2015-02-16 |
| IL233086A0 (en) | 2014-07-31 |
| BR112014014464A2 (en) | 2017-06-13 |
| EP2790724A1 (en) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190576T1 (en) | Methods of preparation of conjugates | |
| HK1244183A1 (en) | Deuterated derivatives of ivacaftor | |
| IL265707A (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
| HK1203364A1 (en) | Use of n-hydroxysuccinimide to improve conjugate stability n- | |
| HK1212261A1 (en) | Methods of tissue generation | |
| HUE047354T2 (en) | Deuterated derivatives of ivacaftor | |
| HK1197068A1 (en) | Methods for preparation of glycosphingolipids and uses thereof | |
| EP2665733A4 (en) | Preparation of metal-triazolate frameworks | |
| EP2670761A4 (en) | Preparation of metal-catecholate frameworks | |
| EP2764325A4 (en) | Using videogrammetry to fabricate parts | |
| EP2852403A4 (en) | Methods for modification of tissues | |
| IL236312A0 (en) | Preparation of 18f-fluciclovine | |
| GB2491882B (en) | Improvements to letterboxes | |
| EP2684869A4 (en) | Preparation of 3-mercaptopropionates | |
| EP2758421A4 (en) | Compositions and methods related to tissue targeting | |
| PL395425A1 (en) | Preparation of 2-amino-N-tert-butyl-2-cyanoacetamide hydrochloride | |
| GB201104632D0 (en) | Use of medicament | |
| PL395618A1 (en) | Device for enhancing stability of muscle fibers | |
| PT3326648T (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
| GB201113502D0 (en) | Synthesis preparation and formation of shiphonated lirocene | |
| IL212131A0 (en) | Two halves of ahearf are joimed to test acoople's comptisility | |
| UA22469S (en) | DETAIL OF SHAPED COMPRESSION TEE BODY |